FDA delays decision on Mannkind's Afrezza

Officials with MannKind, a pharmaceutical company in Danbury, have announced that the Food and Drug Administration has delayed its decision on Afrezza, an inhaled insulin, that was originally slated for April 15. The company said the decision has been extended to July 15 to give the FDA more time to do a full review of information submitted by ... (more)



via Danbury Newswire http://ift.tt/1eiW5ZC